Search

Your search keyword '"Sakuma, Masashi"' showing total 409 results
Start Over Author "Sakuma, Masashi"
409 results on '"Sakuma, Masashi"'

1. Clinical usefulness of phase angle as an indicator of muscle wasting and malnutrition in inpatients with cardiovascular diseases

Author

Yokomachi, Jun, Fukuda, Taira, Mizushima, Yuta, Nozawa, Naohiro, Ishizaka, Hayato, Matsumoto, Kazuhisa, Kambe, Takahiro, Inoue, Shohta, Nishikawa, Kaori, Toyama, Yohei, Takahashi, Reiko, Arakawa, Tomoe, Yagi, Hiroshi, Yamaguchi, Suomi, Ugata, Yuusuke, Nakamura, Fumitaka, Sakuma, Masashi, Abe, Shichiro, Fujita, Hideo, Mizushima, Takashi, Toyoda, Shigeru, and Nakajima, Toshiaki

Published
2023

5. Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial

Author

Shimizu, Yuuki, Kondo, Kazuhisa, Hayashida, Ryo, Sasaki, Ken-ichiro, Ohtsuka, Masanori, Fukumoto, Yoshihiro, Takashima, Shinichiro, Inoue, Oto, Usui, Soichiro, Takamura, Masayuki, Sakuma, Masashi, Inoue, Teruo, Nagata, Tokuichiro, Akashi, Yoshihiro J., Yamada, Yoshihiro, Kato, Tamon, Kuwahara, Koichiro, Tateno, Kaoru, Kobayashi, Yoshio, Shibata, Rei, and Murohara, Toyoaki

Published
2022
Full Text
View/download PDF

6. Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events

Author

Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Kimura, Takeshi, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Miyauchi, Katsumi, Daida, Hiroyuki, Suwa, Satoru, Sakuma, Ichiro, Nishihata, Yosuke, Saito, Yasushi, Ogawa, Hisao, Matsuzaki, Masunori, Ohashi, Yasuo, Taguchi, Isao, Toyoda, Shigeru, Inoue, Teruo, and Nagai, Ryozo

Published
2022
Full Text
View/download PDF

7. Left atrial reservoir strain is a marker of atrial fibrotic remodeling in patients undergoing cardiovascular surgery: Analysis of gene expression.

Author

Nakajima, Toshiaki, Haruyama, Akiko, Fukuda, Taira, Minami, Kentaro, Hirose, Suguru, Yazawa, Hiroko, Nakajima, Takafumi, Hasegawa, Takaaki, Kitagawa, Yoshiyuki, Obi, Syotaro, Inami, Shu, Oguri, Gaku, Shibasaki, Ikuko, Amano, Hirohisa, Arikawa, Takuo, Sakuma, Masashi, Abe, Shichiro, Fukuda, Hirotsugu, and Toyoda, Shigeru

Subjects
ATRIAL flutter, LEFT heart atrium, GENE expression, SPECKLE tracking echocardiography, REVERSE transcriptase polymerase chain reaction, CARDIOVASCULAR surgery
Abstract

Left atrial strain (LAS) measured by two-dimensional speckle tracking echocardiography (2DSTE) is considered to be a marker of LA structural remodeling, but it remains unsettled. We investigated the potential usefulness and clinical relevance of LAS to detect atrial remodeling including fibrosis by analyzing gene expression in cardiovascular surgery patients. Preoperative 2DSTE was performed in 131 patients (92 patients with sinus rhythm [SR] patients including paroxysmal AF [PAF], 39 atrial fibrillation [AF]) undergoing cardiovascular surgery. Atrial samples were obtained from the left atrial appendages, and mRNA expression level was analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR) in 59 cases (24 PAF, 35 AF). Mean value of left atrial reservoir strain (mLASr) correlated with left atrial volume index (LAVI), and left atrial conduit strain (mLAScd). mLASr also correlated with left atrial contractile strain (mLASct) in SR patients including PAF. mLASr was significantly lower, and LAVI was higher, in the AF group, compared with SR patients including PAF. The expression of COL1A1 mRNA encoding collagen type I α1 significantly increased in AF patients (p = 0.031). mLASr negatively correlated with COL1A1 expression level, and multivariate regression analysis showed that mLASr was an independent predictor of atrial COL1A1 expression level, even after adjusting for age, sex, and BMI. But, neither mLAScd / mLASct nor LAVI (bp) correlated with COL1A1 gene expression. The expression level of COL1A1 mRNA strongly correlated with ECM-related genes (COL3A1, FN1). It also correlated ECM degradation-related genes (MMP2, TIMP1, and TIMP2), pro-fibrogenic cytokines (TGFB1 encoding TGFβ1, END1, PDGFD, CTGF), oxidant stress-related genes (NOX2, NOX4), ACE, inflammation-related genes (NLRP, IL1B, MCP-1), and apoptosis (BAX). Among the fibrosis-related genes examined, univariable regression analysis showed that log (COL1A1) was associated with log (TGFB1) (adjusted R2 = 0.685, p<0.001), log (NOX4) (adjusted R2 = 0.622, p<0.001), log (NOX2) (adjusted R2 = 0.611, p<0.001), suggesting that TGFB1 and NOX4 was the potent independent determinants of COL1A1 expression level. mLASr negatively correlated with the ECM-related genes, and fibrosis-related gene expression level including TGFB1, NOX2, and NLRP3 in PAF patients. PAF patients with low mLASr had higher expression of the fibrosis-related gene expression, compared with those with high mLASr. These results suggest that LASr correlates with atrial COL1A1 gene expression associated with fibrosis-related gene expression. Patients with low LASr exhibit increased atrial fibrosis-related gene expression, even those with PAF, highlighting the utility of LAS as a marker for LA fibrosis in cardiovascular surgery patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Can we diagnose sarcopenia using anterior femoral muscle thickness in patients with cardiovascular disease?

Author

Fukuda, Taira, primary, Yokomachi, Jun, additional, Yamaguchi, Suomi, additional, Yagi, Hiroshi, additional, Shibasaki, Ikuko, additional, Ugata, Yuusuke, additional, Sakuma, Masashi, additional, Yasuda, Tomohiro, additional, Abe, Shichiro, additional, Fukuda, Hirotsugu, additional, Fujita, Hideo, additional, Toyoda, Shigeru, additional, and Nakajima, Toshiaki, additional

Published
2024
Full Text
View/download PDF

15. Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model

Author

Migita, Suguru, Kitano, Daisuke, Li, Yuxin, Koyama, Yutaka, Shimodai-Yamada, Sayaka, Onishi, Akira, Fuchimoto, Daiichiro, Suzuki, Shunichi, Nakamura, Yoshiyuki, Matsuyama, Taka-aki, Hirota, Seiichi, Sakuma, Masashi, Tsujimoto, Masahiko, Hirayama, Atsushi, Okumura, Yasuo, and Hao, Hiroyuki

Published
2021
Full Text
View/download PDF

23. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol—study protocol

Author

Sakuma, Masashi, Toyoda, Shigeru, Arikawa, Takuo, Koyabu, Yota, Kato, Toru, Adachi, Taichi, Suwa, Hideaki, Narita, Jun-ichi, Anraku, Koetsu, Ishimura, Kimihiko, Yamauchi, Fumitake, Sato, Yasunori, Inoue, Teruo, and For Excited UA study Investigators

Published
2018
Full Text
View/download PDF

32. Immunoglobulin G4-related inflammatory pseudotumor of the right ventricle with right coronary artery occlusion

Author

Shibasaki, Ikuko, primary, Nakajima, Takahiro, additional, Matsuoka, Taiki, additional, Kanno, Yasuyuki, additional, Kanazawa, Yuta, additional, Takei, Yusuke, additional, Tuchiya, Go, additional, Saito, Shunsuke, additional, Konishi, Taisuke, additional, Sakuma, Masashi, additional, Toyoda, Shigeru, additional, and Fukuda, Hirotsugu, additional

Published
2022
Full Text
View/download PDF

33. Association between serum GDF-15, myostatin, and sarcopenia in cardiovascular surgery patients

Author

Nishikawa, Riichi, primary, Fukuda, Taira, additional, Haruyama, Akiko, additional, Shibasaki, Ikuko, additional, Yamaguchi, Suomi, additional, Arikawa, Takuo, additional, Obi, Syotaro, additional, Amano, Hirohisa, additional, Yagi, Hiroshi, additional, Sakuma, Masashi, additional, Abe, Shichiro, additional, Fukuda, Hirotsugu, additional, Toyoda, Shigeru, additional, and Nakajima, Toshiaki, additional

Published
2022
Full Text
View/download PDF

36. Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)

Author

Shimomura, Mitsuhiro, Oyama, Jun-ichi, Takeuchi, Masayoshi, Shibata, Yoshisato, Yamamoto, Yusuke, Kawasaki, Tomohiro, Komoda, Hiroshi, Kodama, Kazuhisa, Sakuma, Masashi, Toyoda, Shigeru, Inoue, Yohei, Mine, Daigo, Natsuaki, Masahiro, Komatsu, Aiko, Hikichi, Yutaka, Yamagishi, Sho-ichi, Inoue, Teruo, and Node, Koichi

Published
2016
Full Text
View/download PDF

39. Effects of the factor Xa inhibitor rivaroxaban on the differentiation of endothelial progenitor cells.

Author

Sohma, Ryoichi, Sakuma, Masashi, Obi, Syotaro, Nishino, Setsu, Inoue, Ken-ichi, Kishimoto, Satoko, Lu, Tianyang, Toyoda, Shigeru, and Inoue, Teruo

Subjects
VASCULAR endothelial growth factor receptors, PROGENITOR cells, ENDOTHELIAL cells, VASCULAR endothelial cells, RIVAROXABAN
Abstract

Background: We evaluated the efficacy of the factor Xa inhibitor rivaroxaban on the differentiation ability of vascular endothelial progenitor cells (EPCs), which play roles in vascular injury repair and atherogenesis. Antithrombotic treatment in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) is challenging, and current guidelines recommend oral anticoagulant monotherapy 1 year or more after PCI. However, biological evidence of the pharmacological effects of anticoagulants is insufficient. Methods: EPC colony-forming assays were performed using peripheral blood-derived CD34-positive cells from healthy volunteers. Adhesion and tube formation of cultured EPCs were assessed in human umbilical cord-derived CD34-positive cells. Endothelial cell surface markers were assessed using flow cytometry, and Akt and endothelial nitric oxide synthase (eNOS) phosphorylation were examined using western blot analysis of EPCs. Adhesion, tube formation and endothelial cell surface marker expression was observed in EPCs transfected with small interfering RNA (siRNA) against protease-activated receptor (PAR)-2. Finally, EPC behaviors were assessed in patients with atrial fibrillation undergoing PCI in whom warfarin was changed to rivaroxaban. Results: Rivaroxaban increased the number of large EPC colonies and increased the bioactivities of EPCs, including adhesion and tube formation. Rivaroxaban also increased vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, Tie-2, and E-selectin expression as well as Akt and eNOS phosphorylation. PAR-2 knockdown increased the bioactivities of EPCs and endothelial cell surface marker expression. Patients in whom the number of large colonies increased after switching to rivaroxaban showed better vascular repair. Conclusions: Rivaroxaban increased the differentiation ability of EPCs, leading to potential advantages in the treatment of coronary artery disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Relationship Between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients With Diabetes and Mild Heart Failure: Results From the CANDLE Trial

Author

Nakatani, Daisaku, Dohi, Tomoharu, Hikoso, Shungo, Tanaka, Atsushi, Nanasato, Mamoru, Shimizu, Wataru, Node, Koichi, Sakata, Yasushi, Ajioka, Masayoshi, Ako, Junya, Amano, Rie, Anzai, Toshihisa, Asai, Mitsutoshi, Dohi, Kaoru, Eguchi, Kazuo, Eshima, Kenichi, Fujiki, Shinya, Fujita, Masashi, Hikoso, Shungo, Hiramitsu, Shinya, Hoshide, Satoshi, Hoshino, Akihiko, Ikeda, Yuki, Ikehara, Yumi, Inomata, Takayuki, Inoue, Teruo, Ishii, Katsuhisa, Ishizaka, Nobukazu, Ito, Masaaki, Iwahashi, Noriaki, Iwakura, Katsuomi, Kadokami, Toshiaki, Kamiya, Haruo, Kanbara, Takahiro, Kanzaki, Yumiko, Kashimura, Ken, Kida, Keisuke, Kimura, Kazuo, Kishi, Satoru, Kitada, Shuichi, Kiyosue, Akihiro, Kodama, Kazuhisa, Kojima, Takayuki, Kondo, Takumi, Kubota, Yoshiaki, Kusunose, Kenya, Machii, Noritaka, Matsunaga, Kazuo, Matsuo, Yasuto, Matsuzawa, Yashushi, Mikami, Takeshi, Minamino, Toru, Nagai, Takahiro, Nagano, Yasuko, Nagumo, Masashi, Nakamura, Ikuko, Nakamura, Katsunori, Nakatani, Daisaku, Nanasato, Mamoru, Naruse, Hiriyuki, Nishino, Masami, Niwano, Shinichi, Oguri, Mitsutoshi, Ohte, Nobuyuki, Oikawa, Masayoshi, Okumura, Takahiro, Okumura, Masanori, Onishi, Katsuya, Ozaki, Yukio, Saito, Kan, Sakamoto, Tomohiro, Sakata, Yasushi, Sakuma, Masashi, Sekino, Hisakuni, Shiina, Kazuki, Shimabukuro, Michio, Shimizu, Wataru, Suzuki, Makoto, Suzuki, Kunihiro, Takahama, Hiroyuki, Takahashi, Naohiko, Takeishi, Yasuchika, Tamaki, Shunsuke, Tanaka, Akihiro, Tanimoto, Syuzo, Teragawa, Hiroki, Tobushi, Tomoyuki, Toita, Takafumi, Tokuda, Kotaro, Tomiyama, Hirofumi, Tsutsui, Hiroyuki, Uehara, Hiroki, Uematsu, Masaaki, Watada, Hirotaka, Yahagi, Kazuyuki, Yamada, Takahisa, Yamada, Hirotsugu, Yoshida, Tatsuya, and Yoshihisa, Akiomi

Abstract

Supplemental Digital Content is Available in the Text.There were few clinical studies on the relationship between sodium glucose cotransporter 2 inhibitors (SGLT2i) and hematopoiesis in patients with diabetes (DM) and heart failure (HF) with consideration of systemic volume status. A total of 226 DM patients with HF enrolled in the CANDLE trial, a multicenter, prospective, randomized open-label blinded-endpoint trial, were studied. Estimated plasma volume status (ePVS) was calculated based on a weight- and hematocrit-based formula. At baseline, there was no significant difference in hematocrit and hemoglobin between the canagliflozin (n = 109) and glimepiride (n = 116) groups. Hematocrit and hemoglobin at 24 weeks, changes in hematocrit and hemoglobin difference (24 weeks-baseline), and hematocrit and hemoglobin ratio (24 weeks/baseline) were significantly higher in the canagliflozin than in the glimepiride group, respectively. There was no significant difference in ePVS at baseline and 24 weeks between the 2 groups. After adjustment for baseline parameters, canagliflozin correlated positively with changes in hematocrit and hemoglobin difference, and hematocrit and hemoglobin ratio by multivariate linear regression analyses. The difference in hematocrit and hemoglobin between the 2 groups became statistically significant at 3 and 6 months after randomization. There was no heterogeneity between canagliflozin and the characteristics of the patients for hematocrit and hemoglobin difference and ratio. A correlation of the changes in hematocrit and hemoglobin with cardiac and renal improvement was not observed. In conclusion, canagliflozin was associated with an increased hematocrit and hemoglobin in patients with diabetes and HF regardless of their volume status and characteristics.

Published
2023
Full Text
View/download PDF

44. Relationship between the serum GDF-15 concentration and muscle function in female patients receiving aortic valve replacement (TAVR, SAVR): Comparison with healthy elderly female subjects

Author

Fukuda, Taira, primary, Nakajima, Toshiaki, additional, Yazawa, Hiroko, additional, Hirose, Suguru, additional, Yokomachi, Jun, additional, Kato, Takashi, additional, Nishikawa, Riichi, additional, Koshiji, Nobuo, additional, Tokura, Michiaki, additional, Nasuno, Takahisa, additional, Nishino, Setsu, additional, Obi, Syotaro, additional, Shibasaki, Ikuko, additional, Kanaya, Tomoaki, additional, Nakamura, Fumitaka, additional, Fukuda, Hirotsugu, additional, Abe, Shichiro, additional, Sakuma, Masashi, additional, and Toyoda, Shigeru, additional

Published
2022
Full Text
View/download PDF

46. Additional file 3 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events

Author

Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Kimura, Takeshi, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Miyauchi, Katsumi, Daida, Hiroyuki, Suwa, Satoru, Sakuma, Ichiro, Nishihata, Yosuke, Saito, Yasushi, Ogawa, Hisao, Matsuzaki, Masunori, Ohashi, Yasuo, Taguchi, Isao, Toyoda, Shigeru, Inoue, Teruo, and Nagai, Ryozo

Abstract

Additional file 3: Table S3. Assessment for the deviation from time-constant assumption for hazard ratios. Asterisks exhibit correlation between the Schoenfeld residuals and rank-transformed time at events. Daggers mean that P value is based on Chi-square test for time-constant hazard ratio.

Published
2022
Full Text
View/download PDF

47. Additional file 4 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events

Author

Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Kimura, Takeshi, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Miyauchi, Katsumi, Daida, Hiroyuki, Suwa, Satoru, Sakuma, Ichiro, Nishihata, Yosuke, Saito, Yasushi, Ogawa, Hisao, Matsuzaki, Masunori, Ohashi, Yasuo, Taguchi, Isao, Toyoda, Shigeru, Inoue, Teruo, and Nagai, Ryozo

Abstract

Additional file 4: Figure S1. The cumulative martingale residuals (blue, thick line) plotted against 10-mg/dl LDL-C levels above the threshold value set by each model to check the linearity assumption in the Cox models, accompanied by 1000 resampled zero-mean random Gaussian processes (black, thin lines). If the relationship between LDL-C above the threshold and event hazards is actually linear in the Cox model (i.e., the linearity assumption holds), the cumulative sum of martingale residuals will approximately follow the zero-mean Gaussian process and fluctuate randomly. The supremum of the cumulative martingale residuals along the LDL-C levels can be tested against the suprema from randomly sampled zero-mean Gaussian processes. A small p-value from this resampling-based test would provide evidence against the linearity assumption.

Published
2022
Full Text
View/download PDF

48. Additional file 1 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events

Author

Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Kimura, Takeshi, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Miyauchi, Katsumi, Daida, Hiroyuki, Suwa, Satoru, Sakuma, Ichiro, Nishihata, Yosuke, Saito, Yasushi, Ogawa, Hisao, Matsuzaki, Masunori, Ohashi, Yasuo, Taguchi, Isao, Toyoda, Shigeru, Inoue, Teruo, and Nagai, Ryozo

Abstract

Additional file 1: Table S1. LDL-C category-specific event rates (pitavastatin 4 mg/day group). Data are adjusted for gender, age (

Published
2022
Full Text
View/download PDF

49. Additional file 2 of Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events

Author

Sakuma, Masashi, Iimuro, Satoshi, Shinozaki, Tomohiro, Kimura, Takeshi, Nakagawa, Yoshihisa, Ozaki, Yukio, Iwata, Hiroshi, Miyauchi, Katsumi, Daida, Hiroyuki, Suwa, Satoru, Sakuma, Ichiro, Nishihata, Yosuke, Saito, Yasushi, Ogawa, Hisao, Matsuzaki, Masunori, Ohashi, Yasuo, Taguchi, Isao, Toyoda, Shigeru, Inoue, Teruo, and Nagai, Ryozo

Abstract

Additional file 2: Table S2. LDL-C category-specific event rates (pitavastatin 1 mg/day group). Data are adjusted for gender, age (

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results